LMP744 Enters Phase 2 Trials for Recurrent Glioblastoma After Phase 1 Shows Tumor Control in 35% of Patients

Glioblastoma is among the most treatment-resistant cancers known to medicine. Standard care - surgery, radiation, and chemotherapy with temozolomide - has not substantially changed the median survival of approximately 15-18 months in newly diagnosed patients for three decades. When tumors recur, which they almost inevitably do, the prognosis deteriorates further: life expectancy after first recurrence is typically six to nine months, and the treatment options are limited.

Gibson Oncology, a private clinical-stage pharmaceutical company based in Miami, has announced the beginning of Phase 2 clinical trials for LMP744, a small molecule drug designed to attack glioblastoma through two simultaneous mechanisms. The trials target first-time recurrent glioblastoma patients and were approved by both the Food and Drug Administration and the National Institutes of Health following the completion of Phase 1 studies.

What LMP744 Does

LMP744 combines inhibition of topoisomerase 1 - an enzyme that cancer cells require to replicate their DNA - with reduction of overexpression of the cMYC oncogene. The cMYC gene is a master regulator of cell growth and metabolism that is overexpressed in a large proportion of glioblastomas and many other cancers. Overactive cMYC drives rapid cell proliferation and suppresses normal cell death pathways, making it a logical target for intervention.

The dual-action approach reflects a recognition that glioblastoma cells have multiple mechanisms for evading single-target therapies. By attacking both DNA replication and the oncogenic signaling that sustains rapid growth, LMP744 aims to make it harder for cancer cells to develop resistance. Whether this dual mechanism translates into clinical benefit beyond what single-mechanism drugs achieve is precisely what the Phase 2 trial is designed to determine.

Phase 1 Results That Supported Progression

Two Phase 1 trials involving more than 40 heavily pretreated, advanced-stage cancer patients - including patients with cancers other than glioblastoma - provided the safety and preliminary efficacy data that supported FDA approval of the Phase 2 protocol. LMP744 proved to be well tolerated in these patients.

Preliminary efficacy signals were modest but notable for a drug tested in heavily pretreated patients with few remaining options: two patients (approximately 5%) experienced tumor reductions of at least 30% in size, meeting the standard partial response criterion. Thirty-five percent of patients achieved disease stabilization - no tumor growth - for periods lasting up to 18 months. In the context of recurrent glioblastoma, disease stabilization for 18 months represents a substantial extension of the typical post-recurrence timeline.

Phase 1 trials are primarily designed to establish safety and dosing, not to measure efficacy, and these numbers come from a small, mixed-cancer patient population. They provide a rationale for proceeding to Phase 2 but cannot predict how LMP744 will perform specifically in recurrent glioblastoma patients.

Phase 2 Design

The trial will enroll approximately 40 patients with first-time recurrent glioblastoma. Each patient will receive a once-daily, one-hour infusion of LMP744 for five consecutive days as an initial treatment cycle. Biological analyses will be performed on brain tissue obtained before and after this initial treatment period, using paired biopsy samples to assess whether LMP744 is reaching the tumor and producing the expected molecular changes.

"The primary endpoint of the study is to evaluate tumor regression in patients with recurrent glioblastoma. Secondary endpoints will evaluate parameters such as progression-free survival, biological changes in glioblastoma tissues obtained pre- and post-treatment, self-reported quality of life and overall survival," said Gibson Oncology CEO Randy Riggs.

If biological results from the initial cycle are favorable, treatment will continue for 12 cycles total. Each cycle consists of five days of treatment followed by 23 days of recovery - a schedule designed to balance drug exposure with tolerability in a patient population that may have limited physiological reserves following prior surgery, radiation, and chemotherapy.

The Challenge Ahead

Glioblastoma has an extensive history of Phase 2 trials that showed promise but did not lead to approved therapies. The blood-brain barrier limits drug penetration into tumor tissue; glioblastoma cells are genetically heterogeneous and develop resistance rapidly; and the tumor microenvironment suppresses immune responses that might otherwise help control cancer growth.

LMP744's dual mechanism addresses some of these challenges but not all. The paired tissue biopsy approach in Phase 2 is particularly important: if the biological data do not show evidence that the drug is reaching the tumor and modulating cMYC and topoisomerase 1 in the expected ways, progression to further development would not be scientifically justified regardless of clinical outcomes.

Gibson Oncology is also evaluating LMP400, a related compound, in collaboration with Dr. Matthew Waitkus at Duke University for high-grade gliomas that are resistant to standard therapies - expanding the company's portfolio beyond LMP744's current Phase 2 indication.